Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $44.83.

A number of analysts have recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Benchmark dropped their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. dropped their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Finally, Wells Fargo & Company reiterated an "overweight" rating and set a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research note on Friday, May 23rd.

Omnicell Trading Up 0.7%

NASDAQ OMCL traded up $0.19 during mid-day trading on Thursday, hitting $27.97. The company's stock had a trading volume of 509,288 shares, compared to its average volume of 562,715. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.75. The stock's fifty day simple moving average is $29.02 and its two-hundred day simple moving average is $34.41. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. The firm has a market capitalization of $1.31 billion, a P/E ratio of 60.81, a price-to-earnings-growth ratio of 8.17 and a beta of 0.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same quarter last year, the firm posted $0.03 earnings per share. Omnicell's revenue for the quarter was up 9.5% compared to the same quarter last year. Research analysts expect that Omnicell will post 1.09 EPS for the current year.

Institutional Trading of Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue increased its stake in shares of Omnicell by 8.7% in the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company's stock worth $819,000 after buying an additional 2,242 shares during the last quarter. Accurate Wealth Management LLC increased its stake in shares of Omnicell by 26.9% in the second quarter. Accurate Wealth Management LLC now owns 45,850 shares of the company's stock worth $1,365,000 after buying an additional 9,719 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after buying an additional 458 shares during the last quarter. Inspire Investing LLC increased its stake in shares of Omnicell by 9.2% in the first quarter. Inspire Investing LLC now owns 9,878 shares of the company's stock worth $345,000 after buying an additional 834 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Omnicell in the first quarter worth $5,635,000. Institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.